NEWS & EVENTS
A team of researchers including NIBIB investigator Kit Lam at the University of California Davis has discovered a new class of nanoparticles capable of packaging a diverse array of drugs. Research findings demonstrate structural and dynamic changes within nanoparticles during interaction with blood proteins which will result in better designed nanomedicines that will be therapeutically more efficacious. Read the full article from ACSNano.
Led by a grant from the National Science Foundation (NSF), Mark Chance, PhD, director of the Center for Proteomics and Bioinformatics at Case Western Reserve University School of Medicine, has been awarded $4 million for work with the National Synchrotron Light Source II (NSLS II) at Brookhaven National Laboratory in New York. Read the full news release from Medicus.
Dr. Joachim Kohn, AFIRM's Director and an NIBIB Principal Investigator, takes people ravaged by war and helps discover new ways to put them (literally) back together through tissue engineering, renerative processes like bone and nerve repair, face transplants, human transplantation, and an engineered skin substitute for burns. Read the full article from Wired.com.
A new study by University of Kentucky researchers, carried out in the laboratory of Pexiuan Guo, an NIBIB PI, shows promise for developing ultrastable RNA nanoparticles that may help treat cancer and viral infections by regulating cell function and binding to cancers without harming surrounding tissue. Read the full article from University of Kentucky.
Point-of-care tests for chlamydia as developed by NIBIB-funded researcher Charlotte Gaydos are more cost-effective than traditional nucleic acid amplification test (NAAT) in a clinic when specified characteristics (sensitivity, specificity, cost, and willingness to wait in a clinic for POC test results) are met. Read the full article from Johns Hopkins.